Radiopharmaceutical tracers for cardiac imaging
Abstract
Cardiovascular disease (CVD) is the leading cause of death and disease burden worldwide. Nuclear myocardial perfusion imaging with either single-photon emission computed tomography or positron emission tomography has been used extensively to perform diagnosis, monitor therapies, and predict cardiovascular events. Several radiopharmaceutical tracers have recently been developed to evaluate CVD by targeting myocardial perfusion, metabolism, innervation, and inflammation. This article reviews old and newer used in nuclear cardiac imaging.
Read the paper
Related studies
- Developing high safety Li-metal anodes for future high-energy Li-metal batteries: strategies and perspectives
- Structure and Energy Transfer in Photosystems of Oxygenic Photosynthesis
- Ground- and Space-Based Gamma-Ray Astronomy
- Energy Functions in De Novo Protein Design: Current Challenges and Future Prospects
- Electronic structure of ions and molecules in solution: a view from modern soft X-ray spectroscopies
- Arising 2D Perovskites for Ionizing Radiation Detection
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.